Plasmacytoma in thyroid cartilage  by Alvarez Gracia, A.
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S289–S305 S299
Average pain relief: OXN −4; OP −2,5; (p<0.01). – Both clinically and signiﬁcantly favorable bowel function change, in patients
treated with OXN −19.5 vs OP +6.5 (p<0.01).
Conclusions. Cancer patients treated with opioids signiﬁcantly improve their QOL. Maintained opioid treatment with OXN shows
signiﬁcant improvements in QOL, pain relief and bowel function.
http://dx.doi.org/10.1016/j.rpor.2013.03.387
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Introduction. Laryngeal plasmacytomas are very uncommon and few cases are described. We present a patient with multiple
myeloma who has been diagnosed with thyroid cartilage plasmocytoma.
Case. 74 year-old man diagnosed in 2004 of a solitary vertebral plasmacytoma treated with external beam radiotherapy at D5 level.
In 2009, multiple plasmocytomas evidenced along vertebral column. New irradiation was desestimated because of the previous
treatment. Was treated by arthrodesis (D2–D7). A new progression in 2010 was treated with corticoids. He was diagnosed of an
IgAl oligosecreator myeloma and started melfalan-bortezomib-prednisone therapy, achieving a complete response after 6 cycles.
In 2012 was detected swelling in left zygomatic area. Tomographic scanner showed a lytic lesion in left orbit with extension to
the zygomatic bone. Histologic study conﬁrmed plasmacytoma. External beam radiotherapy 30Gy was done at this level with
a partial response. During CT simulation, we detected a new lytic lesion in the thyroid cartilage with associated soft tissue
involvement. For now, is pending perform radiotherapy (20Gy) and subsequent systemic treatment.
Discussion. Plasma cell neoplasms are characterized by neoplastic proliferation of a single clone of plasma cells. They can
present as solitary plasmacytoma (SP), extramedullary plasmacytoma (EP) and multiple myeloma. Solitary plasmacytomas most
frequently occur in bone, involving large bones and axial skeleton. Head and neck location is not frequent. Extramedullary
plasmacytomas (EP) affect submucosal areas and are most often located in head and neck region (80%), mainly in the upper
aerodigestive tract, althought uncommon laryngeal location (<7%). EP can arise in patients with multiple myeloma at any time
during the course of the disease. Plasmacytomas are radiosensitive tumors. Radiotherapy in these tumors may provide a good
local control and symptomatic control of the disease.
Conclusion. Plasmacytomas located in laryngeal area are very uncommon. It is needed and histological conﬁrmation and radio-
therapy is a good treatment option.
http://dx.doi.org/10.1016/j.rpor.2013.03.388
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Background. Medulloblastoma is one of the most common childhood brain malignancies.
Aim. The purpose of this study is to evaluate the tolerability and prognostic factors for toxicity of craniospinal irradiation (CSI)
with helical tomotherapy (HT) in the treatment of medulloblastoma.
Materials and methods. The study was conducted for 19 pediatric patients with primary medulloblastoma (standard risk, N=10;
high risk, N=9) treated with craniospinal HT from May 2007 through December 2010. HT regimens to the neuroaxis included:
23.4Gy at 1.8Gy/fraction (N=10), 36Gy at 1.8Gy/fraction (N=7), and 39Gy bid at 1.3Gy/fraction (N=2). The tumor bed received
54–60Gy at 1.5–1.8Gy/fraction. Spearman’s rank correlation coefﬁcient was used to correlate patient, tumor, and dosimetric
factors with the grade of acute toxicity or the overall survival time.
Results. The median age at diagnosis was 5 years (range, 2–14) and the median follow-up for alive patients (N=14) 40 months
(range, 10–62). Two and three-year overall survival was 75% and 68%, respectively. Only 2 patients had a local failure in the
surgical bed. The most common acute toxicity was hematological (79%), being grade 2 and grade 3 in 4 (21%) and 11 (58%) cases,
respectively. Speciﬁcally, grade 3 acute anemia, neutropenia, and thrombopenia was observed in 5% (N=1), 53% (N=10), and 10%
(N=2), respectively. Therewere no cases of grade 4 acute toxicity. Non grade ≥2 late toxicitieswere observed. Longer time between
diagnosis and radiation therapy associated with shorter overall survival (P=0.03). Older children associated with higher grades of
acute body toxicity (P=0.004), whereas longer radiation treatments associated with higher grades of acute hematological toxicity
(P=0.034).
